Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|March 16, 2017
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)Susan R Rheingold, Sarah K Tasian, James A Whitlock, et al.
Pediatric Blood & Cancer|July 21, 2016
Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemiaWeili Sun, Etan Orgel, Jemily Malvar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Communicating and understanding the purpose of pediatric phase I cancer trialsMelissa K Cousino, Stephen J Zyzanski, Amy D Yamokoski, et al.
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
Medical Care|March 14, 2012
Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative dataBrian T Fisher, Tracey Harris, Kari Torp, et al.
Molecular Syndromology|August 17, 2023
Co-Occurrence of Pallister-Killian Syndrome and Burkitt Lymphoma in a Patient with Near-Normal Neurocognitive DevelopmentKosuke Izumi, Rebecca D Ganetzky, Gerald B W Wertheim, et al.
Haematologica|February 1, 2020
Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433Glen Lew, Yichen Chen, Xiaomin Lu, et al.
Pediatric Blood & Cancer|April 10, 2026
Real-World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital-Dispensed ModelKatelyn Oranges, Kelly A Duffy, Sara McDonough, et al.
Blood|May 17, 2013
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyDavid T Teachey, Susan R Rheingold, Shannon L Maude, et al.
The Lancet. Haematology|September 24, 2021
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trialsAllison Barz Leahy, Haley Newman, Yimei Li, et al.
Pageof 9